- Home
- AEXA vs EVO Comparison
AEXA vs EVO Comparison
Compare AEXA & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEXA | EVO |
|---|---|---|
| Founded | 2025 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.2M | 568.6M |
| IPO Year | 2025 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AEXA | EVO |
|---|---|---|
| Price | $10.92 | $1.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.23 |
| AVG Volume (30 Days) | ★ 182.6K | 79.2K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $20.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.49 | $1.33 |
| 52 Week High | $11.99 | $4.12 |
Technical Indicators
Market Signals| Indicator | AEXA | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 53.98 |
| Support Level | $10.70 | $1.50 |
| Resistance Level | $11.41 | $1.97 |
| Average True Range (ATR) | 0.14 | 0.05 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 88.89 | 100.00 |
Price Performance
Historical ComparisonAbout AEXA American Exceptionalism Acquisition Corp. A
American Exceptionalism Acquisition Corp A is a blank check company.
About EVO Evotec SE
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.